Oncotarget:乳腺癌患者具有不同的乳腺微生物群

2017-10-08 海北 MedSci原创

乳腺癌是在全球妇女中最常见的癌症,但是至今为止,至少有一半的患病妇女没有已知的危险因素。只有一部分患者因为乳腺癌遗传倾向,或是暴露于已知的环境危险因素而患病。因此,我们还需要进一步确定其他的乳腺癌危险因素。

乳腺癌是在全球妇女中最常见的癌症,但是至今为止,至少有一半的患病妇女没有已知的危险因素。只有一部分患者因为乳腺癌遗传倾向,或是暴露于已知的环境危险因素而患病。因此,我们还需要进一步确定其他的乳腺癌危险因素。

已有的报导显示,肠道微生物能够通过改变系统雌激素水平来促进乳腺癌的发生。这通常被认为是高脂肪,低纤维饮食,以及抗生素暴露引起乳腺癌的可能机制。最近,研究人员在母乳和乳腺组织中发现了一个独特的微生物组。但是至今为止,对于乳腺癌患者和健康人之间乳腺组织微生物群差异的研究很少,人们的注意力主要集中在肠道微生物。

来自克利夫兰诊所的研究人员提出假设,癌化乳腺组织与良性乳腺组织的微生物学特征不同,此外,口腔和尿道微生物也能够反映生理疾病。为了验证其假设,研究人员招募了57名进行乳房切除手术的浸润性乳腺癌患者,以及21名进行胸部美容外科手术的健康人。研究人员从尿液,口腔冲洗和手术收集的乳腺组织中扩增细菌16S rRNA基因,测序,并通过基于QIIME的生物信息学途径进行处理。

研究人员发现,癌症患者乳腺组织微生物聚集和非癌症患者有着显着的不同(p = 0.03),主要变现为癌症患者乳腺组织中甲基杆菌相对丰度减少(中位数0.10 vs. 0.24,p = 0.03)。口腔冲洗样品无显着性差异。尿液微生物群的差异主要由月经状态解释,围绝经期/绝经后妇女乳酸杆菌水平降低。然而,独立于绝经状态,癌症患者革兰氏阳性菌的丰度上升,包括棒状杆菌(p <0.01),葡萄球菌(p = 0.02),放线菌(p <0.01)和丙酸杆菌科(p <0.01)。

因此,研究结果显示,乳腺癌患者和健康人群的乳腺微生物群是有差别的。乳腺癌患者尿液中革兰氏阳性菌丰度的上升还需要在更大的队列研究中进行验证。


原始出处:

Hannah Wang et al. Breast tissue, oral and urinary microbiomes in breast cancerOncotarget, 2017; DOI: 10.18632/oncotarget.21490


本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824832, encodeId=5f3c182483207, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Aug 08 20:46:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795472, encodeId=aa601e95472ba, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 16 15:46:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367738, encodeId=aed5136e7387c, content=<a href='/topic/show?id=2cee50e22c6' target=_blank style='color:#2F92EE;'>#微生物群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50722, encryptionId=2cee50e22c6, topicName=微生物群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571069, encodeId=097515e1069a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251312, encodeId=fe3425131246, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Sun Oct 08 09:01:56 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251294, encodeId=f55625129432, content=学习了.希望继续研究的成果, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Oct 08 08:32:47 CST 2017, time=2017-10-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824832, encodeId=5f3c182483207, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Aug 08 20:46:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795472, encodeId=aa601e95472ba, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 16 15:46:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367738, encodeId=aed5136e7387c, content=<a href='/topic/show?id=2cee50e22c6' target=_blank style='color:#2F92EE;'>#微生物群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50722, encryptionId=2cee50e22c6, topicName=微生物群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571069, encodeId=097515e1069a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251312, encodeId=fe3425131246, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Sun Oct 08 09:01:56 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251294, encodeId=f55625129432, content=学习了.希望继续研究的成果, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Oct 08 08:32:47 CST 2017, time=2017-10-08, status=1, ipAttribution=)]
    2018-02-16 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824832, encodeId=5f3c182483207, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Aug 08 20:46:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795472, encodeId=aa601e95472ba, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 16 15:46:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367738, encodeId=aed5136e7387c, content=<a href='/topic/show?id=2cee50e22c6' target=_blank style='color:#2F92EE;'>#微生物群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50722, encryptionId=2cee50e22c6, topicName=微生物群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571069, encodeId=097515e1069a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251312, encodeId=fe3425131246, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Sun Oct 08 09:01:56 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251294, encodeId=f55625129432, content=学习了.希望继续研究的成果, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Oct 08 08:32:47 CST 2017, time=2017-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1824832, encodeId=5f3c182483207, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Aug 08 20:46:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795472, encodeId=aa601e95472ba, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 16 15:46:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367738, encodeId=aed5136e7387c, content=<a href='/topic/show?id=2cee50e22c6' target=_blank style='color:#2F92EE;'>#微生物群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50722, encryptionId=2cee50e22c6, topicName=微生物群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571069, encodeId=097515e1069a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251312, encodeId=fe3425131246, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Sun Oct 08 09:01:56 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251294, encodeId=f55625129432, content=学习了.希望继续研究的成果, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Oct 08 08:32:47 CST 2017, time=2017-10-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1824832, encodeId=5f3c182483207, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Aug 08 20:46:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795472, encodeId=aa601e95472ba, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 16 15:46:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367738, encodeId=aed5136e7387c, content=<a href='/topic/show?id=2cee50e22c6' target=_blank style='color:#2F92EE;'>#微生物群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50722, encryptionId=2cee50e22c6, topicName=微生物群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571069, encodeId=097515e1069a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251312, encodeId=fe3425131246, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Sun Oct 08 09:01:56 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251294, encodeId=f55625129432, content=学习了.希望继续研究的成果, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Oct 08 08:32:47 CST 2017, time=2017-10-08, status=1, ipAttribution=)]
    2017-10-08 137****9095

    henhao

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1824832, encodeId=5f3c182483207, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Aug 08 20:46:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795472, encodeId=aa601e95472ba, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 16 15:46:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367738, encodeId=aed5136e7387c, content=<a href='/topic/show?id=2cee50e22c6' target=_blank style='color:#2F92EE;'>#微生物群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50722, encryptionId=2cee50e22c6, topicName=微生物群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571069, encodeId=097515e1069a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Oct 09 22:46:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251312, encodeId=fe3425131246, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Sun Oct 08 09:01:56 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251294, encodeId=f55625129432, content=学习了.希望继续研究的成果, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Oct 08 08:32:47 CST 2017, time=2017-10-08, status=1, ipAttribution=)]
    2017-10-08 明崖

    学习了.希望继续研究的成果

    0

相关资讯

中国抗癌协会乳腺癌诊治指南与规范(2017年版)

中国抗癌协会乳腺癌诊治指南与规范(2017年版)主要内容包括: 1 乳腺癌筛查指南(附录Ⅰ) 2 常规乳腺X线检查和报告规范(附录Ⅱ) 3 乳腺超声检查和报告规范(附录Ⅲ) 4 常规乳腺MRI检查和报告规范(附录Ⅳ) 5 影像引导下的乳腺组织学活检指南 6 乳腺癌术后病理诊断报告规范(附录Ⅴ) 7 浸润性乳腺癌保乳治疗临床指南 8 乳腺癌前哨淋巴结活检临床指南 9 乳腺癌全乳切除术后放疗临床指南

Radiology:乳腺导管内癌根治术后会不会复发?术前定量乳腺MRI特征与治疗后复发的相关性

本研究旨在验证乳腺磁共振(MR)图像中特异征象是否与导管内原位癌(DCIS)根治术后复发风险具有相关性,并将结果发表在Radiology上。

Eur radiol:乳房长肿块了?容积定量动态对比增强MRI在鉴别良恶性乳腺病变的价值

女性乳腺是由皮肤、纤维组织、乳腺腺体和脂肪组成的,乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。乳腺癌中99%发生在女性,男性仅占1%。乳腺癌的早期发现、早期诊断,是提高疗效的关键。应结合患者的临床表现及病史、体格检查、影像学检查、组织病理学和细胞病理学检查(在有条件的医院),进行乳腺癌的诊断与鉴别诊断。本研究旨在验证容积定量动态对比增强MRI(qDCE-MRI)在鉴别良恶性乳腺病变的价值,并将结果发表

Am J Cancer Res:circ-ABCB10通过海绵miR-1271促进乳腺癌的进展

循环RNA(circRNA RNA)是人类癌症发生及发展的关键调节因子,但其在乳腺癌肿瘤发生中的作用尚不清楚。本研究旨在研究circRNA对乳腺癌致癌作用的表达谱及其潜在的调控机制。使用人circRNA微阵列筛选乳腺癌组织中异常表达的circRNA。结果发现circBBB10在乳腺癌组织中明显上调。且扩大样本量进行筛查结果亦是如此。体外功能丧失实验显示,敲除circ-ABCB10可抑制乳腺癌细胞的

Radiology:雌激素受体阳性乳腺癌复发风险?定性放射基因学组来说道说道!

乳腺癌Breast Cancer是目前全球女性中发病最高的恶性肿瘤,是一种全身性疾病,乳腺位置及乳腺癌示意图在早期即可发生腋淋巴结转移,因此在治疗策略上早期发现并阻断其转移对乳腺癌的治疗及预后具有重大的临床意义。而浸润性乳腺癌是乳腺癌的主要类型严重危害着女性的身心健康。本研究旨在评价雌激素受体阳性乳腺癌患者乳腺影像学报告和数据系统(BI-RADS)乳腺X线摄影和磁共振(MR)成像特征与乳腺复发风险

Oncotarget:我国学者研究证实:蛇床子素可抑制乳腺癌骨转移

晚期乳腺癌患者骨转移发生率达到70%左右,且首发为骨转移者占27%-50%。骨痛、骨损伤等骨相关事件是乳腺癌骨转移常见的并发症,并严重影响患者自主活动能力,降低了患者生活质量。